Full-Time
Professional organization for family physicians
No salary listed
Junior, Mid
Leawood, KS, USA
Hybrid position; possible 6-10 days travel annually.
The American Academy of Family Physicians (AAFP) focuses on supporting family physicians and promoting the specialty of family medicine. It offers a variety of resources including continuing medical education (CME) courses, journals, and practice management tools to help physicians stay updated on medical practices and improve patient care. AAFP's products, such as mobile applications and self-study packages, assist physicians in managing their practices and enhancing their medical knowledge. Unlike other medical organizations, AAFP emphasizes the unique role of family medicine and advocates for policies that benefit family physicians and their patients. The goal of AAFP is to advance the practice of family medicine and ensure that family physicians have the resources they need to provide high-quality care.
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Leawood, Kansas
Founded
1947
Help us improve and share your feedback! Did you find this helpful?
Hybrid Work Options
NEW YORK, June 9, 2025 /PRNewswire/ -- VERB Products, the destination for salon-quality haircare at one set affordable price, announces the launch of its latest innovation: the Density Peptide Collection, a two-step system scientifically developed to target thinning hair and visible signs of shedding
After Obamacare slapped a 10% tax on tanning bed services, Nicole "Snooki" Polizzi launched her Sunless Tanning Collection. (She's shown here at a 2012 launch event.) Spray-on tans are exempt from the tax, which Republicans now want to repeal. Ed Rode/Getty Images). Tucked among the trillions of tax cuts in the House’s just-passed “big, beautiful bill” is the repeal of the tax on indoor tanning services. But before you rush to book a tanning bed appointment, remember that the Senate still has to act on this bill and that dermatologists are no fans of tanning. About The Tax
Semaglutide 1 mg demonstrated statistically significant and superior improvement in maximum walking distance by 13% over placebo in adults with type 2 diabetes and symptomatic PAD 1Based on STRIDE trial data, presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo while simultaneously published today in The Lancet , Novo Nordisk submitted a label extension application accepted for review by the FDAApproximately 12 million people in the United States are impacted by PAD, a form of atherosclerotic disease, and one in four also have type 2 diabetes2,3PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic® (semaglutide) injection 1 mg in adults with type 2 diabetes and early-stage symptomatic PAD1, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo. The results were presented during a late-breaking clinical trial session and highlighted at an official ACC press conference. In addition, the analysis was also simultaneously published today in The Lancet.The double-blind, randomized, placebo-controlled STRIDE trial, which enrolled 792 adults with type 2 diabetes and symptomatic PAD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 13% superior improvement in maximum walking distance (estimated treatment ratio [ETR] vs placebo, 1.13; 95% confidence interval [CI], 1.06 to 1.21; p=0.0004) and a clinically meaningful median treatment difference of 26.4 meters (95% CI, 11.8 to 40.9; approximately 87 feet, or about a third the length of an American football field) on a 12% incline, compared to placebo at 52 weeks. The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed, including pain-free walking distance (ETR vs placebo 1.11; 95% CI, 1.03 to 1.20; p=0.0046) and Vascular Quality of Life Questionnaire-6 (VascuQoL-6) (estimated treatment difference vs placebo 1.00; 95% CI, 0.48 to 1.52; p=0.011) at 52 weeks.1,4"Peripheral artery disease (PAD) may cause severe symptoms, physical limitations, and a diminished quality of life, often making even short walks—such as retrieving the mail—challenging. In individuals with PAD and diabetes, the disease can be even more severe, affecting small blood vessels and limiting the effectiveness of revascularization procedures and other treatments. Semaglutide 1 mg is the first medication in over two decades to show meaningful improvements in functional capacity and quality of life, which could address a critical unmet need for those with both PAD and type 2 diabetes," said Marc P
VANCOUVER, BC, Jan. 27, 2025 /PRNewswire/ - The U.S. wound and tissue management market is a highly competitive industry with multiple competing segments positioned as substitutes for one another. This intense competition will limit market growth despite the otherwise strong presence of major drivers of growth including demographic factors, rising rates of diabetes, obesity, and favorable Medicare policies. Competition is further driven by a constant need to innovate to avoid the commoditization of products within the market which would lead to price competition and slim profit margins. The US market for wound and tissue management is expected to grow to reach nearly $16 billion USD by 2030
Submissions will be reviewed by the AAFP Nominating Committee, which was established at the 2023 Congress of Delegates.